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Pentadecapeptide BPC 157 is intraduced as therapy in a suprahepatic inferior caval vein (ICV) 
occlusion 15 min, 24h, 48h after complete ICV ligation. Suprahepatic ICV complications that were 
counteracted by BPC 157 included esophageal bleeding, severe portal and caval hypertension, and 
aortal hypotension. Likewise, BPC 157 counteracts the lesions in the whole GI-tract. Medication (BPC 
157 (10 μg/kg, 10 ng/kg), or saline (5 ml/kg) (controls)) was applied as an abdominal bath immediately 
after ICV occlusion. ICV occlusion produced severe esophageal bleeding in all controls, along with 
microscopy findings. Contrarily, given in ischemic period, BPC 157 counteracts severe esophageal 
bleeding and maintained grossly intact esophageal mucosa . In rats with ICV occlusion, assessment of 
portal (PV), caval (ICV) and aortal (AA) pressure showed huge portal hypertension and more caval 
hypertension, along with mild aortic hypotension (15 min: 68±4 PV, 45±4 ICV, 73±3 AA; 24 h: 56±5 
PV, 49±5 ICV, 35±3 AA; 48 h 30±3 PV, 48±5 ICV, 39±3 AA-ligation period). Contrarily, BPC 157 in 
rats with suprahepatic ICV occlusion markedly counteracted portal and caval hypertension, and arterial 
hypotension (10 μg/kg bath 15 min: 3±1 PV, 9±1 ICV, 117±5 AA; 24 h: 5±1 PV, 9±1 ICV, 67±5 AA; 
48 h: 5±1 PV, 9±1 ICV, 70±6 AA), 10 ng/kg bath produced similar results. BPC 157 therapy 
successfully counteracts the adverse effects of the suprahepatic ICV occlusion. 
 
  
